×
AllNewsImages Maps Videos Books
Search tools

Pfizer Inks $1.25 Billion Deal with 3SBio for Global Rights to Cancer Drug

Contract Pharma
Pfizer Inks $1.25 Billion Deal with 3SBio for Global Rights to Cancer Drug. SSGJ-707 has shown initial efficacy and safety data in a promising...
1 month ago

Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific, joining red-hot race with BioNTech, Merck

Fierce Biotech
Pfizer made a splashy entrance late Monday, revealing it is paying $1.25 billion upfront and committing up to $4.8 billion in milestones for ex-...
1 month ago

Pfizer buys into PD-1/VEGF competition with 3SBio deal

BioPharma Dive
Pfizer buys into PD-1/VEGF competition with 3SBio deal. Pfizer will pay China's 3SBio $1.25 billion up front to access a cancer drug that works...
1 month ago

Pfizer Enters into Exclusive Licensing Agreement with 3SBio

Business Wire
Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese...
1 month ago

3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

BioWorld MedTech
3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race ... 3Sbio Inc. reported interim phase II study results of its PD-1/VEGF...
3 weeks ago

Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake

Reuters
US drugmaker Pfizer (PFE.N) said it would license an experimental cancer treatment from China's 3SBio Inc (1530.HK), paying $1.25 billion upfront.
1 month ago

Pfizer licenses cancer bispecific antibody from Chinese developer 3SBio in $1.25 billion bid

BioProcess International
Pfizer has entered an exclusive licensing agreement with Chinese biologic developer 3SBio for the development, manufacturing, and commercialization of...
1 month ago

Pfizer Puts $6B on the Line for 3SBio’s PD-1/VEGF Antibody

BioSpace
Pfizer is paying $1.25 billion upfront in a licensing pact with 3SBio, gaining access to the Chinese biotech's PD-1/VEGF bispecific antibody for...
1 month ago

3SBio Inc. Announces AGM Results, Dividend Payment, and Committee Changes

TipRanks
3SBio ( ($HK:1530) ) has issued an announcement. 3SBio Inc. announced the results of its Annual General Meeting (AGM) held on June 25, 2025,...
1 week ago

Pfizer strikes $1.25 billion licensing deal with Chinese biopharma 3SBIO

Medical Marketing and Media
Pfizer strikes $1.25 billion licensing deal with Chinese biopharma 3SBIO. The pharma giant entered an exclusive agreement with the Chinese...
1 month ago